sábado, 14 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 17, 2026

Boards protected CEO bonuses as tariffs threatened business. Now, as Iran disrupts trade, CEOs may get more protection

View original at finance.yahoo.com
Boards protected CEO bonuses as tariffs threatened business. Now, as Iran disrupts trade, CEOs may get more protection When Apple CEO Tim Cook and his executive team received their performance targets for fiscal 2025, the board set a modest bar for bonus payouts…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Boards are having conversations about approaches they might consider at year end regarding Iran conflict impact

    60% confidence
  • Committee focused on underlying business performance rather than absolute growth rates when setting targets

    60% confidence
  • Calendar year companies approved 2026 goals about two or three days before Iran news broke, giving no opportunity to incorporate conflict into goal setting

    60% confidence
  • Board set fiscal 2025 performance targets at same level or below prior year's results citing 'trade policy' and 'uncertain macroeconomic outlook'

    60% confidence
  • If companies make adjustments and give executives big payouts during significant layoffs, the optics would be seen negatively in the press

    60% confidence
  • Companies that made tariff carve-outs last year might still consider using that lever this year if tariffs significantly impact them

    60% confidence
  • Committee set goals that reflect strong financial results commensurate with projected business and economic conditions

    60% confidence
  • Companies setting targets with their budget still align them to what finance thinks is achievable

    60% confidence
  • Uncertainty about Iran conflict duration makes it like looking into a crystal ball

    60% confidence
  • Tariffs had unexpected magnitude on financial results and incentive calculations after goals had been set

    60% confidence
  • Companies will look for precedent in how boards responded to Iraq invasion in 2003

    60% confidence
  • The intent when goals are set is to account for what is in and out of executive team's control and set realistic goals

    60% confidence
  • Target incentive goals should be achievable but stretch to align executive pay with shareholder experience

    60% confidence
  • Tariff adjustments reflect net impact after management actions including shifting 30% of manufacturing from China to Southeast Asia and Mexico

    60% confidence
  • Companies can widen performance curves and adjust targets to make it easier for executives to earn bonuses

    60% confidence
  • Some improvement in weak performer bonuses is due to business improvement, but companies also softened the blow through various compensation techniques

    60% confidence

Data points we hold from this source

HP Inc. · manufacturing shift percentage30 percent
HP Inc. · bonus payout percentage67.3 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com
Boards protected CEO bonuses as tariffs threatened business. Now, as Iran disrupts trade, CEOs may get more protection — Source | Via News | es.VIA.NEWS